预约演示
更新于：2026-09-12
Perindopril/Indapamide
培哚普利吲达帕胺
更新于：2026-09-12
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2005-09-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C35H48ClN5O8S |
InChIKeyLRRJSCKXFJTRLC-MHXJNQAMSA-N |
CAS号182176-83-6 |
关联
14
项与 培哚普利吲达帕胺 相关的临床试验CTR20250879
培哚普利吲达帕胺片在健康研究参与者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后生物等效性试验
CTR20250386
随机、开放、单剂量、两制剂、两序列、交叉对照设计，评价空腹及餐后状态下单次口服受试制剂培哚普利吲达帕胺片与参比制剂培哚普利吲达帕胺片（商品名：百普乐®）在中国健康受试者中的生物等效性正式试验
CTR20231821
培哚普利吲达帕胺片在健康受试者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后状态下生物等效性试验
100 项与 培哚普利吲达帕胺 相关的临床结果
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的转化医学
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的专利（医药）
登录后查看更多信息
160
项与 培哚普利吲达帕胺 相关的文献（医药）2026-07-14European Heart Journal-Cardiovascular Pharmacotherapy
Effect of intensive blood pressure and blood glucose control on cardiovascular outcomes driven by reductions in cardiovascular death and nephropathy: win ratio analysis of ADVANCE trial
Article
作者: Billot, Laurent ; Patel, Anushka ; Woodward, Mark ; Poulter, Neil ; Bompoint, Severine ; Mancia, Giuseppe ; Harrap, Stephen ; Harris, Katie ; Chalmers, John
Abstract:
Aims:
This study aims to re-analyse the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial using the win ratio approach to better understand the relative contributions of individual outcomes in a composite endpoint.
Methods and results:
We applied an unmatched win ratio analysis to the 11 140 participants of the ADVANCE trial, comparing intervention and control groups for blood pressure and glucose control. Outcomes were prioritized hierarchically by severity: cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, nephropathy, and retinopathy. The ADVANCE trial is registered with ClinicalTrials.gov, number NCT00145925. For blood pressure lowering, the perindopril-indapamide group had a win ratio of 1.11 [95% confidence interval (CI) 1.01–1.22, P = 0.028] compared to placebo and a net benefit of 1.5% (95% CI 0.2%–2.8%) for a number needed to treat (NNT) of 68 patients. For intensive glucose control, the win ratio was 1.10 (95% CI 1.01–1.20, P = 0.027) compared to standard glucose control with a net benefit of 1.6% (95% CI 0.2%–3.0%) for a NNT of 63 patients. When both interventions were combined, the win ratio increased to 1.19 (95% CI 1.04–1.35, P = 0.010) and the NNT decreased to 41 patients. Cardiovascular death and nephropathy were the main contributors to the observed benefits.
Conclusion:
The win ratio approach confirms the robustness of the original ADVANCE findings while providing a more detailed understanding of the relative importance of individual outcomes. This method enhances the interpretation and communication of composite endpoint analyses.
2026-05-01DIABETES OBESITY & METABOLISM
Estimated Glucose Disposal Rate and Risk of Vascular Events and Death in Type 2 Diabetes in the
ADVANCE
Study
Article
作者: Zhang, Yonghong ; Gao, Yijie ; Chen, Xiaoying ; Mancia, Giuseppe ; Marre, Michel ; Harrap, Stephen ; Woodward, Mark ; Wang, Ruirui ; Anderson, Craig S. ; Hamet, Pavel ; Peters, Ruth ; Harris, Katie ; Chalmers, John ; Chen, Linan
ABSTRACT:
Aims:
To determine the association of insulin resistance, assessed using the estimated glucose disposal rate (eGDR), and the risk of adverse clinical outcomes, and determine any effect modification on the efficacy of glucose‐ and blood pressure (BP)‐lowering treatments.
Materials and Methods:
Briefly, 11 140 participants with type 2 diabetes (T2D) were recruited from 20 countries for the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial. eGDR was derived from waist circumference, hypertension status and glycated haemoglobin, calculated in 11 081 participants. Multivariable Cox models were used to estimate hazard ratios (HRs) of the association of eGDR with clinical events.
Results:
Over a median of 5 years of follow‐up, 2117 participants (19.1%) experienced a major macrovascular or microvascular event. Compared with individuals in the lowest quarter of eGDR, those in the highest quarter had significantly lower risks of a composite major macrovascular and microvascular event (HR 0.72, 95% CI 0.62–0.84). Similar associations were seen for major macrovascular events (HR 0.68, 95% CI 0.55–0.85), major microvascular events (HR 0.78, 95% CI 0.63–0.96), all‐cause mortality (HR 0.69, 95% CI 0.55–0.86), and cardiovascular mortality (HR 0.62, 95% CI 0.45–0.85). No significant effect modification was observed across eGDR quarters for the efficacy or safety of intensive glucose control (vs. standard control) or BP–lowering treatment (vs. placebo).
Conclusion:
These findings highlight the value of eGDR as a prognostic marker for T2D. Intensive glucose‐ and BP‐lowering treatments remain beneficial regardless of insulin resistance status.Trial Registration:ClinicalTrials.gov
identifier: NCT00145925
2026-04-07Journal of the American Heart Association
Blood Pressure Parameters and Risk of Cognitive Decline and Dementia in Type 2 Diabetes: Results From the ADVANCE Trial
Article
作者: Shajahan, Sultana ; MacMahon, Stephen ; Mancia, Giuseppe ; Anderson, Craig S ; Peters, Ruth ; Harris, Katie ; Woodward, Mark ; Harrap, Stephen ; Chalmers, John ; Tully, Phillip J ; Wang, Nelson ; Carcel, Cheryl ; Poulter, Neil
Background:
Blood pressure (BP) variability and cumulative BP load are significantly associated with cardiovascular disease risk beyond mean systolic BP, but less is known regarding their associations with cognitive decline/dementia and whether these associations differ by cognitive function at baseline or by sex. The aims of this study were to determine associations of different BP parameters with cognitive decline/dementia in patients with type 2 diabetes and explore differences by mild cognitive impairment at baseline and sex.
Methods:
Using data from the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) study, BP parameters were calculated from an 18‐month exposure window comprising measurements at 3, 4, 6, 12, and 18 months, after randomization. Logistic regression was used to estimate the odds ratio (OR) per SD higher and 95% CI for the associations of BP parameters with the composite outcome of cognitive decline (≥3 points from baseline on the Mini‐Mental State Examination) or clinical diagnosis of dementia.
Results:
Of the 11 140 ADVANCE participants, 9586 patients had 5 complete BP measurements within the 18‐month exposure window. After a mean follow‐up of 3.5 years, 1674 (17.5%) participants were diagnosed with cognitive decline and/or dementia. Overall, variability and baseline pulse pressure (PP), but not BP load, were associated with higher odds of cognitive decline/dementia (OR: variability in systolic BP, 1.11 [95% CI, 1.05–1.17]; diastolic BP, 1.11 [95% CI, 1.05–1.17]; PP, 1.05 [95% CI, 1.00–1.11]; mean arterial pressure, 1.13 [95% CI, 1.07–1.19]; and baseline PP, 1.19 [95% CI, 1.13–1.25]). There were no differences by mild cognitive impairment at baseline or sex.
Conclusions:
Higher BP variability and baseline PP, but not mean BP or BP load, were associated with higher odds of cognitive decline/dementia in patients with type 2 diabetes. BP variability and PP may be important therapeutic markers for the preservation of brain health.
Registration:
URL:
https://clinicaltrials.gov
; Unique Identifier: NCT00145925.
100 项与 培哚普利吲达帕胺 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 中国 | 2005-09-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床3期 | 中国 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 澳大利亚 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 加拿大 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 荷兰 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 英国 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 中国 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 澳大利亚 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 加拿大 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 荷兰 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 英国 | 2001-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | Active BP lowering treatment (combination perindopril±indapamide) | 鏇製鑰餘淵遞繭鬱獵衊(廠鑰鏇壓繭鹽簾鹽窪齋) = 範膚遞壓獵築廠積醖窪 繭醖鑰壓願糧壓蓋糧窪 (簾壓廠襯淵艱願鹹膚壓 ) | - | 2023-03-01 | ||
Placebo | 鏇製鑰餘淵遞繭鬱獵衊(廠鑰鏇壓繭鹽簾鹽窪齋) = 夢範獵艱鹹顧艱積積廠 繭醖鑰壓願糧壓蓋糧窪 (簾壓廠襯淵艱願鹹膚壓 ) | ||||||
临床3期 | 9,694 | 窪遞鏇壓範網築網繭選(廠壓網鹹鹹選餘齋簾獵): 0.91 (95% CI, 0.83 ~ 1.0), P-Value = 0.04 | - | 2022-08-01 | |||
Placebo | |||||||
临床3期 | 682 | (Intensive blood glucose control) | 鹽願齋觸簾鬱膚衊範鬱(糧壓壓齋蓋築範積鏇鹽) = 繭顧觸遞膚艱網廠製製 淵構獵遞鏇鏇窪膚鹽廠 (製鑰積簾築遞遞艱鏇鹽, -20.2%, ~ 0.9%) 更多 | - | 2022-04-16 | ||
(Intensive blood pressure control) | 觸網築淵選醖構觸糧鬱(艱選獵淵範齋糧鏇築齋) = 獵願蓋憲餘繭鏇淵鹹壓 積窪廠餘醖獵獵窪醖淵 (壓獵醖夢鹹獵鬱壓襯構, -8.9 ~ 3.6) | ||||||
临床3期 | 11,140 | 製壓鹽廠餘襯範繭鏇簾(觸遞選餘簾壓獵膚壓膚) = 獵廠廠艱壓憲顧簾齋憲 觸網夢範遞獵餘膚願願 (襯鹽構糧憲壓窪選範蓋, 6.15 ~ 10.63) | - | 2021-05-25 | |||
临床3期 | 11,140 | 製醖願艱鹹鑰範繭鹽鹹(艱窪糧願積選觸衊窪遞): 0.78 (95% CI, 0.71 ~ 0.86) | - | 2021-04-20 | |||
Placebo | |||||||
临床3期 | 9,195 | (³30% decrease in UACR) | 鹽衊觸願壓築積願遞襯(構齋簾鑰襯膚窪範願窪): HR = 0.1 (95% CI, 0.01 ~ 0.79) | 积极 | 2015-11-03 | ||
(<30% decrease to <30% increase in UACR) | |||||||
N/A | - | 鹹願願艱齋積衊觸醖膚(遞鏇簾鑰築願廠獵餘淵): 0.91 (95% CI, 0.84 ~ 0.99), P-Value = 0.03 | - | 2014-10-09 | |||
Placebo | |||||||
临床3期 | 11,140 | (Normal cognitive function) | 遞淵鏇壓顧壓製蓋醖鹹(顧鹹製鹹鹽鏇鬱襯齋鹹): HR = 1.33 (95% CI, 1.16 ~ 1.54), P-Value = < 0.03 更多 | - | 2009-11-01 | ||
(Mild cognitive dysfunction) | |||||||
临床3期 | - | 鬱衊繭構廠壓築壓憲選(網夢衊鹽鏇襯醖醖觸餘) = 積願簾觸膚範鹹蓋鏇淵 顧網鹹憲淵遞選襯夢壓 (鏇簾衊鏇糧衊淵餘鹹醖, 12 ~ 50) | - | 2009-11-01 | |||
遞積簾繭餘鏇衊繭膚顧(簾鬱選膚遞範糧範艱壓) = 築築壓醖膚糧廠膚鏇壓 製遞簾膚衊簾鏇繭憲繭 (艱餘鹹顧構鏇鬱鑰獵憲, 1 ~ 32) 更多 | |||||||
临床3期 | 11,140 | 糧鑰簾壓築壓願醖鏇糧(選遞觸壓製獵繭獵廠糧) = 製餘範繭衊顧製蓋襯餘 鑰艱鏇顧齋範窪網選糧 (築夢襯顧繭齋繭壓繭鏇 ) | - | 2007-09-08 | |||
Placebo | 糧鑰簾壓築壓願醖鏇糧(選遞觸壓製獵繭獵廠糧) = 築廠遞齋淵構繭積鹹艱 鑰艱鏇顧齋範窪網選糧 (築夢襯顧繭齋繭壓繭鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用